Clinical Management of Dravet Syndrome and Related Epilepsies

Dravet syndrome is a rare, severe developmental and epileptic encephalopathy typically arising in infancy, characterised by prolonged febrile and afebrile seizures, progressive cognitive and motor impairment, and a high risk of status epilepticus. Most cases result from pathogenic variants in the SCN1A gene, which encodes a voltage‐gated sodium channel subunit critical for neuronal excitability. Early genetic confirmation not only secures diagnosis but also informs avoidance of sodium‐channel blocking drugs. First‐line pharmacotherapy commonly includes valproate combined with clobazam and stiripentol or newer agents such as fenfluramine and cannabidiol. Adjunctive approaches encompass ketogenic dietary therapies, neurostimulation techniques and multidisciplinary support for behavioural, sleep and movement comorbidities. Across related SCN1A‐positive epilepsies with milder phenotypes, management principles emphasise precise genetic classification, tailored anti‐seizure medication regimens and monitoring for learning, behavioural and motor sequelae. Care of adults with Dravet syndrome mandates transition planning, continued seizure surveillance and provision of social and psychological support for caregivers. Recent advances in gene therapy and antisense oligonucleotides signal the emergence of precision interventions, though clinical implementation remains in early stages. A coordinated, lifelong care model is essential to mitigate seizure burden, optimise development and reduce caregiver distress on a global scale.

Research from Nature Portfolio

In a multicentre study of children and adolescents with Dravet syndrome in Spain, investigators characterised clinical management patterns and quality‐of‐life outcomes. Despite seizure onset before six months of age, median time to diagnosis exceeded six years, underscoring persistent delays. Over 85 per cent of patients carried confirmed SCN1A mutations and nearly three‐quarters experienced seizures in the preceding year, predominantly generalised tonic‐clonic events. Status epilepticus remained a recurrent challenge with a mean of 3.6 episodes since diagnosis. Health utility scores revealed substantial deficits, with mean global indices below 0.6 on standard multi-attribute scales and severe disease impact for over 80 per cent of participants. Carer well‐being assessments highlighted widespread mental and physical strain, despite high satisfaction with caregiving roles. The study emphasises the need for earlier genetic testing, standardised treatment algorithms and integrated support services to address both patient and caregiver quality of life.

Clinical Management of Dravet Syndrome and Related Epilepsies publication trend

The graph below shows the total number of articles in clinical management of dravet syndrome and related epilepsies across all publications each year (not limited to Nature Index journals).

Technical terms

Dravet syndrome: A severe developmental and epileptic encephalopathy linked to SCN1A mutations, marked by drug-resistant seizures and neurodevelopmental impairment.

Developmental and epileptic encephalopathy (DEE): A group of disorders in which epileptic activity contributes to cognitive and behavioural regression beyond baseline development.

SCN1A: The gene encoding the alpha subunit of the neuronal voltage-gated sodium channel NaV1.1, mutations of which underlie most Dravet syndrome cases.

Anti-seizure medication (ASM): Pharmacological agents used to reduce the frequency and severity of epileptic seizures.

Status epilepticus: A prolonged seizure or series of seizures without full recovery of consciousness, representing a neurological emergency.

Precision medicine: A therapeutic approach that tailors interventions to individual genetic, molecular or clinical profiles to maximise efficacy and minimise adverse effects.

References

1. Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain. Scientific Reports (2023).
2. Clinical and Genetic Features of Dravet Syndrome: A Prime Example of the Role of Precision Medicine in Genetic Epilepsy. International Journal of Molecular Sciences (2023).
3. Long-term predictors of developmental outcome and disease burden in SCN1A-positive Dravet syndrome. Brain Communications (2023).
4. Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe. Epilepsia Open (2021).